Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Aug 15, 2026; 18(8): 119966
Published online Aug 15, 2026. doi: 10.4251/wjgo.v18.i8.119966
Published online Aug 15, 2026. doi: 10.4251/wjgo.v18.i8.119966
Table 2 Comparison of survival indicators between the two groups of patients (mean ± SD)
| Survival indicators | Experimental group (n = 45) | Control group (n = 45) | χ2/t | P value |
| Median progression-free survival (months) | 8.9 ± 0.4 | 4.7 ± 0.5 | 43.265 | < 0.001 |
| Median overall survival (months) | 16.8 ± 1.2 | 10.3 ± 1.0 | 25.782 | < 0.001 |
- Citation: Sheng C, Li H. Impact of sintilimab plus anlotinib on progression-free survival in advanced unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(8): 119966
- URL: https://www.wjgnet.com/1948-5204/full/v18/i8/119966.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i8.119966